Bio-Techne Corp (TECH) Peer Comparison
$72.35
$-0.12
(-0.17%)
As on 28-Aug-2026 16:03EDT
Market cap
$11,346 Mln
Revenue (TTM)
$1,215 Mln
P/E Ratio
62.4
P/B Ratio
5.4
Div. Yield
0.4 %
Edit
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
11,346 | 21,673 | 14,038 | 10,953 | 8,904 |
Revenue ($ Mln) |
1,215 | 1,183 | 3,999 | -- | -- |
Net Profit ($ Mln) |
181.86 | -453.44 | -238.46 | -856.09 | -1,064.26 |
Net Margin (%) |
14.97 | -38.33 | -5.96 | -- | -- |
RoE (%) |
9.03 | -- | -8.01 | -153.01 | -39.10 |
Price to Earnings |
62.37 | -- | -- | -- | -- |
Price-To-Book |
5.39 | 55.67 | 4.88 | 18.16 | 3.30 |
Income Statement ($ Mln)
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,215.04 | -- | -- | -- | -- |
|
Cost of Revenue
|
415.97 | -- | -- | -- | -- |
|
Gross Profit
|
799.07 | -- | -- | -- | -- |
|
Operating Expenses
|
547.18 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
251.89 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
240.68 | -- | -- | -- | -- |
|
Provision for Tax
|
58.82 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
181.86 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,108.22 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
407.07 | -- | -- | -- | -- |
|
Current Liabilities
|
163.70 | -- | -- | -- | -- |
|
Total Liabilities
|
2,678.99 | -- | -- | -- | -- |
Assets ($ Mln)
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,934.59 | -- | -- | -- | -- |
|
Current Assets
|
744.40 | -- | -- | -- | -- |
|
Total Assets
|
2,678.99 | -- | -- | -- | -- |
|
Total Debt*
|
289.09 | -- | -- | -- | -- |
|
Net Current Assets
|
580.70 | -- | -- | -- | -- |
Cashflow ($ Mln)
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
292.07 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-18.19 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
-169.11 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
7.64 | -- | -- | -- | -- |
|
ROE (%)
|
9.03 | -- | -- | -- | -- |
|
ROA (%)
|
6.95 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
14.97 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.00 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
147.77 | -- | -- | -- | -- |
|
EPS Growth (%)
|
1.46 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
61.00 | -- | -- | -- | -- |
|
Price / Book Value
|
5.26 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
32.37 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.14 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.01 | -- | -- | -- | -- |
|
Current Ratio
|
4.55 | -- | -- | -- | -- |
|
Quick Ratio
|
3.35 | -- | -- | -- | -- |
|
Interest Coverage
|
45.53 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Bio-Techne Corp (TECH) | Guardant Health (GH) | Charles River Laboratories (CRL) | Summit Therapeutics - ADR | Vaxcyte (PCVX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.15 | -- | -- | -- | -- |
|
Asset Turnover
|
0.46 | -- | -- | -- | -- |
|
Receivable days
|
64.24 | -- | -- | -- | -- |
|
Inventory Days
|
169.11 | -- | -- | -- | -- |
|
Payable days
|
22.83 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
210.51 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
